Japan has approved Incyte’s Tabrecta (capmatinib) for certain patients with advanced and/or recurrent unresectable non-small cell lung cancer.

The approval was based on the results of a phase 2 trial, in which the overall response rate for Tabrecta was 68 percent for those patients who had not received any previously prior treatment and 41 percent in previously treated patients.

The approval earns Incyte a $20 million milestone payment from Novartis, which holds worldwide commercial rights to the drug.